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Background: In more than 98% of cases, acromegaly is due to a GH-secreting pituitary adenoma. The term “ectopic
acromegaly” includes neuroendocrine tumors secreting GH releasing hormone (GHRH), usually located in the lungs,
thymus and endocrine pancreas. Considerably less frequent are cases of ectopic acromegaly due to GH-secreting
tumors located out of the pituitary fossa; except for one isolated case of a well-documented GH-secreting
lymphoma, the majority of these lesions are located in the sphenoid sinus.
Case presentation: We present the case of a 45 year old woman with acromegaly whose MRI showed an empty
sella without evidence of a pituitary adenoma but revealed a large mass within the sphenoid sinus. She underwent
transsphenoidal surgery and the excised sphenoid sinus mass, proved to be a GH-secreting adenoma; the sellar floor
was intact and no other lesions were found in the pituitary fossa. She required postoperative treatment with
somatostatin analogs and cabergoline for clinical and biochemical control.
Conclusions: This case highlights the importance of carefully evaluating the structures surrounding the sellar area
when a pituitary adenoma is not found with currently available imaging techniques. The finding of an intact sellar
floor and duramater lead us to conclude that the patient’s tumor originated de novo from embryological pituitary
remnants. Upon a careful review of the literature and a critical evaluation of our case we found neither clinical nor
biochemical features that would distinguish an ectopic from the more common eutopically located
somatotrophinoma.
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Acromegaly results from an excessive GH secretion by
a pituitary adenoma in over 98% of the cases [1]. It is a
relatively rare condition, with a prevalence of 20–40
cases per million and an incidence of 3–4 new patients
per year [1]. In less than 2% of the cases, acromegaly
results from GHRH-secreting neuroendocrine tumors
usually located in the lungs, thymus and endocrine pan-
creas [1,2]. Even less frequent are cases of real ectopic
GH secretion by adenomas arising in pituitary remnants* Correspondence: moises.mercado@endocrinologia.org.mx
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reproduction in any medium, provided the orin this sphenoid sinus or by other neoplastic lesions like
lymphomas [3,4].
Ectopic acromegaly due to a GHRH neuroendocrine
tumor (NET) should be suspected when a patient pre-
sents with all the clinical and biochemical features of
the disease but without evidence of a pituitary adenoma
on MRI [2,5,6]. In this scenario, the pituitary gland may
appear hyperplastic or even normal and the condition
is documented by the demonstration of an elevated
serum GHRH level. What follows is the localization of the
NET by means of high resolution CT and 111In-labeled
octreotide scintigraphy [2,5,6]. The absence of a pituitary
adenoma in a patient with clinical and biochemical evi-
dence of GH excess, should prompt a careful evaluation of
the sphenoid sinus, since pituitary remnants, abnormallyl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In these rare cases MRI of the region can be entirely nor-
mal or may show an empty sella [7].
We here in report the case of a woman with acromeg-
aly without a pituitary lesion in whom GH-secreting ad-
enomatous tissue in the sphenoid sinus proved to be the
source of her hypersomatotrophism.
Case presentation
A 45-year-old woman presented with a 5-year history
of menstrual abnormalities, knee and elbow arthralgias,
hands and feet enlargement, coarsening of facial fea-
tures, fatigue, dental spacing and symptoms of obstruct-
ive sleep apnea (snoring and day-time sleepiness). On
physical exam her blood pressure was 180/100 mmHg,
pulse 80 and regular, weight 65 Kg, height 1.55 m.
She had evident acral enlargement with prominence of
supracilliary arches and nose bridge, prognathism and
dental spacing. Numerous pigmented skin tags were vis-
ible in her anterior chest wall and there was slight
acanthosis nigricans in her neck and axillary regions. Her
thyroid was palpable and somewhat nodular but without
distinct lesions. The diagnosis of acromegaly was con-
firmed by an age adjusted IGF-1 level 4.8 times the upper
limit of normal (ULN) and a basal and post glucose GH
concentrations of 7.7 ng/mL and 2.5 ng/mL, respectively
(Table 1). The rest of anterior pituitary hormones were
normal (Table 1).
MRI revealed an empty sella without clearly defined
intrapituitary lesions. The sphenoid sinus was occupied by
a heterogeneous but mostly hyperintense mass (Figure 1).
CT scan did not reveal any abnormalities of the sellar
floor. 111In-labeled octreotide scintigraphy showed abnor-
mal uptake in the sphenoid sinus (Figure 2).
Upon treatment with octreotide-LAR 20 mg monthly
for 4 months, the patient reported clinical improvement
of her headaches and joint pain, and her GH and IGF-1Table 1 Preoperative hormone levels
Hormone Result Normal range
IGF-1 (ng/mL) 920 84-191
IGF-1 x ULN 4.81 < 1
Basal GH (ng/mL) 7.7 -
Nadir post-glucose GH (ng/mL) 2.5 < 0.4
Prolactin (ng/mL) 12.27 3.4-24.1
LH (mU/mL) 10.4 Postmenopausal range > 10
FSH (mU/mL) 36.4 Postmenopausal range >20
Estradiol (pg/mL) 34.7 12-211
Cortisol (μg/mL) 17.5 5-25
Free T4 (ng/dL) 1.4 0.93-1.70
TSH (mU/L) 1.95 0.27-4.20levels decreased to 2.4 ng/mL and 3.5 times the ULN,
respectively. She underwent surgical resection of the
sphenoid sinus mass via an endonasal, transsphenoidal
approach; the surgeon found an intact sellar floor and
duramater. Both structures were opened looking for a
possible intrasellar tumor, but only a protrusion of the
arachnoid membrane into the sella was found. Patho-
logical examination of the resected mass revealed an
acidophilic adenoma on HE and immunohistochemistry
was positive for GH (Figure 3).
Six months postoperatively she still had biochem-
ically active acromegaly despite the absence of a tumor
remnant on postoperative MRI (Figure 1). She was
treated with a combination of octreotide LAR and
cabergoline, eventually achieving an adequate hormonal
control (Figure 4).
Discussion and review of the literature
Pituitary tissue remnants can settle along the embryo-
logical migration and invagination pathway of Rathke’s
pouch [8]. Such remnants have been found in the
mucoperiosteum of the vomerosphenoidal articulation,
the sphenoid bone, or more commonly, within the sphen-
oid sinus [9-11]. Since these embryological remnants lie
out of the hypophyseal-portal system they are unlikely
to be regulated by hypothalamic releasing hormones
[12]. However, some data, albeit controversial, suggest
they can respond to feedback inhibition [12]. Alterna-
tively, the finding of adenomatous pituitary tissue within
the sphenoid sinus can be explained by a pituitary tumor
that protrudes inferiorly due to the pressure exerted by
a large empty sella. This scenario is likely to have oc-
curred when the sellar floor is eroded or frankly absent
with the duramater extending downwards into the sphen-
oid sinus [3,8,10,13-16].
Ectopic acromegaly due to a GH-secreting adenoma
arising from abnormally located pituitary tissue is an ex-
tremely rare entity; barely cases have been reported in
the literature in the past 30 years (Table 2). The most
frequent localization for these ectopic tumors has been
the sphenoid sinus, followed by the clivus and isolated
cases of tumors in the cavernous sinus or the suprasellar
region [3,8-11,13-19]. Clinically, patients present the typ-
ical symptoms and signs of acromegaly. Sinus congestion
symptoms are not commonly reported, which is interest-
ing considering that some of the tumors fully occupy the
sphenoid sinus. Biochemical documentation of acromeg-
aly with varying combinations of basal and post-glucose
GH as well as IGF-1 levels is provided in 10 of these 13
cases; PRL was measured in 7 and found to be elevated
in three. No biochemical features can be found that
would differentiate ectopic from eutopic acromegaly.
Neither the degree of hypersomatotropinemia, nor the




Figure 1 Preoperative (left) and postoperative (right) MRI. A) T1W sagital, gadolinium-enhanced; B) T1W coronal, gadolinium-enhanced;
C) T2W coronal.
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an empty sella. The careful evaluation of the sphenoid
sinus in our patient by MRI revealed the presence of a
mass, which avidly took up 111In-labeled octreotide. Thus,
the possibility that such mass in the sphenoid sinus was in
fact the source of the excessive GH was entertained
preoperatively. To our knowledge, none of the reported
cases of ectopic acromegaly due to ectopically locatedGH-secreting adenomas have been evaluated with oc-
treotide scintigraphy. The GH-secreting nature of the
ectopic tumor was documented by immunohistochem-
istry in 12 of the reported cases; in six, there was con-
comitant, PRL immunostaining (Table 2). There is not
sufficient data to ascertain if these six tumors were real
mammo-somatotrophe adenomas, although that was
likely the case in the three patients who had significant
Coronal Sagital
Figure 2 111In-labeled octreotide scintigraphy showing
abnormal uptake in the sphenoid sinus.
Figure 4 GH and IGF-1 levels at diagnosis, during primary
preoperative therapy with octreotide LAR 20 mg/month, after
surgery, and after postoperative therapy with octreotide LAR
20 mg/month, octreotide LAR 20 mg/month plus cabergoline
(CBG) 1.5 mg/week (1), and octreotide LAR 40 mg/month plus
CBG 1.5 mg/week (2).
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faint PRL immunostaining and yet her serum PRL was
normal.
Among the 9 cases with lesions located in the sphen-
oid sinus, 5 were reported to have bone gaps or ero-
sions of the sellar floor, and duramater defects were
found in one (Table 2). Information regarding surgical
outcome is described in 10 of the 13 cases found in
the literature, with half of them achieving normal
IGF-1 levels. In our case both, the sellar floor and the
duramater were intact and although the duramater was
protruding inferiorly, this could had been the result of
the associated arachnoidocele. Although GH and IGF-1
levels improved after surgery in our patient, she re-
mained biochemically active, and required combination
therapy with high dose octreotide LAR and cabergoline,
as it is frequently the case with eutopically located tu-
mors. We decided against surgical reintervention in
view of the absence of a tumor remnant upon follow up
MRI and the low probability of achieving biochemical
remission [20].
Conclusions
In contrast to the few reported cases with this condi-
tion, our case was fully worked up preoperatively bothFigure 3 Pathology of the resected tumor. Panel A H&E shows an acido
C reveals faint PRL immunostaining in a few cells.biochemically as well as from an imaging standpoint
(MRI and octreoscan scintigraphy); the excised adenoma-
tous tissue was analyzed both by HE and immunohisto-
chemistry for pituitary hormones, and proved to be a
GH-secreting tumor. The surgical findings support the
hypothesis that our patient’s adenoma originated from pi-
tuitary embryological remnants located in the sphenoid
sinus. This is probably the first case of ectopic acromegaly
due to a sphenoid sinus adenoma to be treated successfully
with a combination of a somatostatin analog and a dopa-
mine agonist.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.philic adenoma. Panel B shows strong GH immunostaining and panel
Table 2 Reported cases of ectopic GH-secreting adenomas
Author Bioch. Dx Ectopic location Pituitary Dura Sellar floor IHC
Corenblum, [17] GH 46.8 ng/mL Sphenoid sinus Normal Intact Intact GH++
PRL 5 ng/mL
Warner, [13] — Sphenoid sinus Normal Intact Erosion GH++
PRL+
Maddona, [14] — Sphenoid sinus Normal Intact Erosion GH++
TSH+
Matsuno, [15] GH 97 ng/mL Sphenoid sinus Empty sella Intact Absent GH++
IGF-1 2.3 x ULN PRL+
PRL 140 ng/mL α-SU+
Hori, [16] GH 14.5 ng/mL Sphenoid sinus Empty sella Defect. Absent GH++
PRL 26.3 ng/mL
Mitsuya, [9] GH 133 ng/mL Cavernous sinus Normal Intact Intact GH++
PRL 73 ng/mL PRL+
Gondim, [18] GH 97 ng/mL Sphenoid sinus Empty sella Intact Absent GH++
IGF-1 2.7 x ULN
PRL 17 ng/mL
Chan, [10] — Sphenoid sinus Normal Intact Intact —




Guerrero, [11] GH 12.3 ng/mL Sphenoid sinus Normal Intact Intact GH++
IGF-1 1.9 x ULN
PRL 40.2 ng/mL PRL+
Kurowska, [19] GH 4.3 ng/mL Sphenoid sinus Empty sella ? ? GH++
IGF-1 2.5 x ULN
Appel, [8] GH 6 ng/mL Clivus Empty sella Intact Intact GH++
IGF-1 3.1 x ULN PRL+
PRL 26 ng/mL
Hong, [3] GH 18 ng/mL Sphenoid sinus Empty sella Intact Partially absent GH++
IGF-1 3.6 x ULN
Current case GH 7.7 ng/mL Sphenoid sinus Empty sella Intact Intact GH++
IGF-1 4.8 x ULN PRL+
PRL 12.7 ng/mL
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